

**A STUDY OF THE SUSCEPTIBILITY TO  
MEASLES VIRUS INFECTION AMONGST  
PEDIATRIC ACUTE LYMPHOBLASTIC  
LEUKEMIAS AT THE NATIONAL  
CANCER INSTITUTE IN EGYPT**

رسالة

By

**Samah Aly Loutfy**

B.Sc. 1987

581.1  
S.A

Thesis

*Submitted in Partial Fulfillment For*

*'The Degree of*

**Master of Science**

In

**Botany (Microbiology)**


تم الفحص  
46318

Botany Department - College for Women

Ain Shams University

1993





« وَقُلْ زِدْنِي عِلْمًا »

« صدره الامم العظيم »

سورة طه : آية ( 114 )





## Approval Sheet

**Name** : Samah Aly Loutfy  
**Title** : A study of the susceptibility to measles virus infection amongst pediatric acute lymphoblastic leukemias at the National Cancer Institute in Egypt.

This thesis has been approved by :

**Professor Dr. Mohammed A. M. Attia, Ph.D.,**  
Professor of Virology and Immunology,  
Virology and Immunology Department,  
National Cancer Institute,  
Cairo University.

*M. A. Attia*  
20 4 93

**Professor Dr. Sawsan El Gammal, Ph.D.,**  
Professor of Microbiology,  
Botany Department,  
Women's College,  
Ain Shams University.

*S. El Gammal*  
20 4 93

**Dr. Salah Saleh Abdel Hadi, M.D.**  
Assistant Professor of Pediatric Oncology,  
Pediatric Oncology Department,  
National Cancer Institute,  
Cairo University.

*Salah Saleh Abdel Hadi*

Head of Botany Department

Prof. Dr. Amal Shehab

*Amal Shehab*

## *Acknowledgement*

I am greatly indebted to my main supervisor, Professor Dr. Mohammed A.M. Attia, Professor of Virology and Immunology, National Cancer Institute, Cairo University. It was him who suggested the search point, supervised, and reviewed the manuscript to the last word. It was him who, in a fatherly spirit, guided my first steps in the years of work at NCI, where the entire study has been carried out, through his magnificent talent and great experience. For all this, and much more I owe him everlasting gratitude. Thank you.

I wish to express my deepest gratitude to Professor Dr. Sawsan El Gammal, Professor of Microbiology, Botany Department, Women's Faculty, Ain Shams University, for her generous advice and great support throughout the whole work. Thank you.

I am especially indebted to Dr. Salah Abdel Hadi, Assistant Professor, Pediatric Oncology Department, National Cancer Institute, Cairo University, for his invaluable supervision, criticism. He willingly offered the facilities of his department to serve the purpose of my study. His unlimited help in revising the whole manuscript is tremendously appreciated. Thank you.

I am also indebted to Dr. Mohammed M. Moneer, Specialist of general surgery, for his great effort throughout the work. I greatly appreciate his invaluable guidance, help, advice, and great interest in the work. Thank you.

I wish to thank Dr. M. Tarek Mansour, Lecturer of Virology and Immunology, National Cancer Institute, Cairo University, who helped me in my work. Thank you.

I also wish to thank all of my colleagues in the Virology and Immunology Unit at NCI, Cairo University, for their help and assistance.

## **CONTENTS**

|   | <b>Page</b> |
|---|-------------|
| <b>LIST OF TABLES</b> .....                         | iv          |
| <b>LIST OF FIGURES</b> .....                        | vii         |
| <b>ABBREVIATIONS</b> .....                          | viii        |
| <b>AIM OF WORK</b> .....                            | x           |
| <b>INTRODUCTION</b> .....                           | 1           |
| <b>Leukemia</b> .....                               | 1           |
| History .....                                       | 1           |
| Acute Leukemia .....                                | 2           |
| Chronic Leukemia .....                              | 3           |
| <b>Childhood Acute Lymphoblastic Leukemia</b> ..... | 4           |
| Classification .....                                | 5           |
| Morphological classification .....                  | 5           |
| Immunological classification .....                  | 6           |
| Etiology .....                                      | 7           |
| Irradiation .....                                   | 7           |
| Chemicals .....                                     | 8           |
| Viruses .....                                       | 8           |
| Clinical Presentation.....                          | 9           |
| Physical .....                                      | 9           |
| Laboratory evaluation.....                          | 11          |
| Porgnosis.....                                      | 11          |
| Treatment.....                                      | 13          |
| Induction therapy.....                              | 13          |
| Maintenance therapy.....                            | 13          |
| Treatment of relapsed ALL.....                      | 14          |
| Bone marrow transplantation.....                    | 14          |
| Immunological Profile of ALL .....                  | 15          |
| <b>Measles</b> .....                                | 16          |
| The Infectious Agent.....                           | 16          |
| Morphology.....                                     | 16          |

|   |           |
|---|-----------|
| Chemical composition.....                           | 18        |
| Antigenic structure.....                            | 19        |
| Physical and chemical properties.....               | 19        |
| Propagation of Measles Virus in Tissue Culture..... | 20        |
| Pathogenesis.....                                   | 21        |
| Pathology.....                                      | 22        |
| Clinical Findings.....                              | 23        |
| Laboratory Diagnosis.....                           | 25        |
| Recovery of virus.....                              | 25        |
| Serology.....                                       | 25        |
| Immunity.....                                       | 26        |
| Epidemiology.....                                   | 29        |
| Control.....  | 31        |
| <b>Infection In Childhood Acute Leukemia.....</b>   | <b>33</b> |
| Complications in Childhood Leukemias.....           | 34        |
| Bacterial infection.....                            | 34        |
| Fungal infection.....                               | 35        |
| Viral infection.....                                | 36        |
| <b>Measles infection in leukemic children.....</b>  | <b>38</b> |
| Giant Cell Pneumonia.....                           | 38        |
| Encephalitis.....                                   | 39        |
| <b>MATERIALS AND METHODS.....</b>                   | <b>42</b> |
| Patients.....                                       | 42        |
| History and Physical Examination .....              | 43        |
| Routine Clinical Laboratory Investigations.....     | 43        |
| Collection of Blood and Serum Separation.....       | 43        |
| Serum Inactivation.....                             | 44        |
| Vero Cell Line .....                                | 44        |
| The Virus.....                                      | 47        |
| Virus Assay.....                                    | 47        |
| MicroPlate Neutralization Test (MPNT) .....         | 48        |
| <b>APPENDIX .....</b>                               | <b>50</b> |
| <b>Media, Reagents, and Buffers.....</b>            | <b>50</b> |

|  |     |
|--|-----|
| <b>RESULTS</b> .....                                     | 53  |
| <b>Clinical Findings</b> .....                           | 53  |
| <b>Clinical Laboratory Findings</b> .....                | 62  |
| Bone marrow aspiration.....                              | 62  |
| Hematological .....                                      | 63  |
| Total leukocytic count.....                              | 63  |
| Differential count.....                                  | 63  |
| Platelet count.....                                      | 66  |
| RBCs count and hemoglobin concentration.....             | 66  |
| <b>Immunological Findings</b> .....                      | 70  |
| Screening for Measles NtAb.....                          | 70  |
| Measles NtAb Titer in Relation to Measles History.....   | 70  |
| In normal controls.....                                  | 70  |
| In children with solid tumors .....                      | 77  |
| In children with ALL .....                               | 77  |
| Changes of Measles NtAb Titer With Other Variables ..... | 85  |
| Effect of age.....                                       | 85  |
| Effect of sex.....                                       | 85  |
| Effect of neutropenia .....                              | 90  |
| Effect of total WBCs count .....                         | 90  |
| Effect of RBCs and Hb conc.....                          | 98  |
| Effect of FAB.....                                       | 98  |
| Effect of platelet count.....                            | 98  |
| <b>DISCUSSION</b> .....                                  | 103 |
| <b>CONCLUSIONS</b> .....                                 | 119 |
| <b>SUMMARY</b> .....                                     | 121 |
| <b>REFERENCES</b> .....                                  | 125 |
| <b>ARABIC SUMMARY</b> .....                              |     |

**LIST OF TABLES**

|  | <i>Page</i> |
|--|-------------|
| Table (1) : Presenting characteristics of children with ALL.....   | 10          |
| Table (2) : Prognostic factors in childhood ALL at diagnosis.....  | 12          |
| Table (3) : Structural components of measles virus.....  | 18          |
| Table (4) : Distribution of 75 childhood ALL, 25 solid tumors,<br>and 20 normal controls according to their age and<br>sex.....                    | 54          |
| Table (5) : Age and sex of 75 childhood ALL cases at different<br>stages of their treatment.....   | 55          |
| Table (6) : Clinical and hematological data in 20 childhood<br>ALL cases during pretreatment phase.....  | 56          |
| Table (7) : Clinical and hematological data in 20 childhood ALL<br>cases during induction remission.....   | 57          |
| Table (8) : Clinical and hematological data in 20 childhood ALL<br>cases during prolonged remission.....   | 58          |
| Table (9) : Clinical and hematological data in 15 childhood ALL<br>cases in relapse.....   | 59          |
| Table (10) : Clinical and hematological data in 25 children with<br>solid tumors.....  | 60          |
| Table (11) : Epidemiological data of 20 normal children.....   | 61          |
| Table (12) : Distribution of 75 childhood ALL cases in different<br>treatment groups according to their FAB<br>classification at presentation..... | 64          |
| Table (13) : Total leukocytic count in 75 childhood ALL<br>cases at different stages of their treatment.....                                       | 65          |

|   |    |
|---|----|
| Table (14) : Neutrophil count in 75 childhood ALL cases at different stages of their treatment.....                     | 67 |
| Table (15) : Platelet count in 75 childhood ALL cases at different stages of their treatment.....                       | 68 |
| Table (16) : Hemoglobin concentration in 75 childhood ALL cases at different stages of their treatment.....             | 69 |
| Table (17) : Measles NtAb titer in normal controls.....   | 76 |
| Table (18) : Measles NtAb titer in children with solid tumors....   | 78 |
| Table (19) : Measles NtAb titer in ALL cases at different stages of their treatment.....                                | 79 |
| Table (20) : Measles NtAb titer in ALL cases at pretreatment....  | 80 |
| Table (21) : Measles NtAb titer in ALL cases during induction remission.....  | 81 |
| Table (22) : Measles NtAb titer in ALL cases in prolonged remission.....  | 82 |
| Table (23) : Measles NtAb titer in ALL cases in relapse.....  | 83 |
| Table (24) : Distribution of ALL cases as regards their age at different stages of their treatment.....                 | 86 |
| Table (25) : Measles NtAb titer in ALL cases in relation to their age group at different stages of their treatment..... | 87 |
| Table (26) : Distribution of ALL cases as regards their sex at different stages of their treatment.....                 | 89 |

|  |     |
|--|-----|
| Table (27) : Measles NtAb titer in ALL cases in relation to sex<br>at different stages of their treatment.....   | 91  |
| Table (28) : Distribution of ALL cases as regards their<br>absolute neutrophil count at different stages of<br>treatment.....                                | 93  |
| Table (29) : Measles NtAb titer in ALL cases in relation to<br>absolute neutrophil count at different stages<br>of their treatment .....                     | 94  |
| Table (30) : Distribution of ALL cases as regards their WBCs at<br>presentation.....   | 96  |
| Table (31) : Distribution of NtAb titer in ALL cases in relation<br>to total WBC count at presentation.....  | 97  |
| Table (32) : Distribution of ALL cases as regards their Hb<br>concentration at presentation.....   | 100 |
| Table (33) : Measles NtAb titer in ALL cases in relation<br>to Hb concentration at presentation.....   | 101 |
| Table (34) : Correlation between measles NtAbs in 66 cases of<br>childhood ALL with high titers above 16 and their<br>granulocyte and lymphocyte counts..... | 117 |

**LIST OF FIGURES**

|   | <b>Page</b> |
|---|-------------|
| Fig. (1) : A digrammatic representation of the structure of measles virion.....   | 17          |
| Fig. (2) : Normal uninfected monolayer of Vero cells.....   | 71          |
| Fig. (3) : Strong CPE in Vero cell monolayers in the form of giant cell formation on the third day after addition of the virus (virus control)..... | 72          |
| Fig. (4) : Moderate CPE as a result of different degrees of neutralization of the viral effect with low serum dilution.....                         | 73          |
| Fig. (5) : Strong CPE as a result of different degrees of neutralization of the viral effect with high serum dilution.....                          | 74          |
| Fig. (6) : The viral CPE in microwell titration plates at high dilution of immune serum.....  | 75          |
| Fig. (7) : Changes of measles NtAb titer with stage of treatment and history of measles in ALL cases.....   | 84          |
| Fig. (8) : Changes of measles NtAb titer with age, and stage of treatment in ALL cases. ....  | 88          |
| Fig. (9) : Changes of measles NtAb titer with sex and stage of treatment in ALL cases.....  | 92          |
| Fig. (10) : Changes of measles NtAb titer with stage of treatment in neutropenic and non neutropenic ALL cases.....                                 | 95          |
| Fig. (11) : Measles NtAb titer in relation to total WBC count at presentation.....  | 98          |
| Fig. (12) : Measles NtAb titer in relation to Hb concentration at presentation.....   | 102         |

**ABBREVIATIONS**

|        |   |   |
|--------|---|---|
| AIDS   | : | Acquired immunodeficiency syndrome.               |
| Ag     | : | Antigen.  |
| AL     | : | Acute leukemia.                                   |
| ALL    | : | Acute lymphoblastic leukemia.                     |
| AML    | : | Acute myelogenous leukemia.                       |
| ANLL   | : | Acute non lymphoblastic leukemia.                 |
| AUL    | : | Acute unclassifiable leukemia.                    |
| BMT    | : | Bone marrow transplantation.                      |
| CALLA  | : | Common ALL antigen.                               |
| CF     | : | Complement fixation.                              |
| CLL    | : | Chronic lymphocytic leukemia.                     |
| CML    | : | Chronic myeloid leukemia.                         |
| CMI    | : | Cell mediated immunity.                           |
| CMV    | : | Cytomegalovirus.                                  |
| CPE    | : | Cytopathic effect.                                |
| CR     | : | Complete remission.                               |
| CSF    | : | Cerebrospinal fluid.                              |
| CTL    | : | Cytotoxic T- lymphocytes.                         |
| DMSO   | : | Dimethyl sulphoxide.                              |
| EEG    | : | Electroencephalogram.                             |
| ELISA  | : | Enzyme linked immunosorbent assay.                |
| FAB    | : | French American British.                          |
| FCS    | : | Fetal calf serum.                                 |
| GM-CSF | : | Granulocyte-macrophage colony stimulating factor. |
| HAI    | : | Hemagglutination inhibition.                      |
| Hb     | : | Hemoglobin.                                       |
| HCL    | : | Hairy cell leukemia.                              |
| HSV    | : | Herpes simplex virus.                             |
| HTLV   | : | Human T-lymphotropic virus.                       |

|                    |   |  |
|--------------------|---|--|
| IF                 | : | Immunofluorescence technique.            |
| IFN                | : | Interferon.                              |
| Igs                | : | Immunoglobulins.                         |
| IgA                | : | Immunoglobulin A.                        |
| IgG                | : | Immunoglobulin G.                        |
| IgM                | : | Immunoglobulin M.                        |
| MEM-TC             | : | Minimal essential tissue culture medium. |
| MHC                | : | Major histocompatibility complex.        |
| M&M                | : | Materials and methods.                   |
| MPNT               | : | Microplates neutralization test.         |
| NtAb               | : | Neutralizing antibody.                   |
| PBS                | : | Phosphate buffered saline.               |
| RBCs               | : | Red blood corpuscles.                    |
| SSPE               | : | Subacute sclerosing panencephalitis.     |
| TCID <sub>50</sub> | : | Tissue culture infectious dose 50.       |
| TLC                | : | Total leukocytic count.                  |
| VZV                | : | Varicella zoster virus.                  |
| WBCs               | : | White blood cells.                       |
| TNC                | : | Total neutrophil count.                  |